

Mammotome Marks Key Milestones as It Grows U.S. and Global Presence

Product development efforts drive innovation and growth; Company plans for new product launch in early 2012

PR Newswire

CINCINNATI, Nov. 25, 2011 /PRNewswire/ -- About 16 months after becoming a division of Devicor® Medical Products, Inc., Mammotome – the company that helped create and build the vacuum-assisted breast biopsy market – has made significant progress toward its new product development and growth goals.

"As the only company with a singular focus on breast biopsy, Mammotome is re-focused, re-energized, and re-committed," says CEO Tom Daulton. "We've spent more than a year solidifying our foundation for growth through product development and acquisition efforts. We're excited to start sharing new products and initiatives with the clinicians who've helped to make Mammotome the trusted, market-leading brand it is today."

With the support of a world-class, cross-functional leadership team, Daulton points to the development of next generation products and platforms as the primary driver of growth and innovation. The first of these products – a single insertion, tetherless device for use in ultrasound-guided biopsies – is currently undergoing FDA approval and is slated to be commercially available globally early next year.

In addition to preparing for next year's new products rollout, several major milestones were reached in 2011:

- Mammotome continues to build its global team with the best and brightest talent in the industry, adding approximately 100 new team members in the past year. With offices in the United States, France, Germany, Italy, Japan, China, Korea and Mexico, the company now employs more than 400 people globally.
- A new manufacturing facility in Tijuana, Mexico, is now fully operational. The plant produces nearly all disposable Mammotome products globally.
- Devicor acquired the neoprobe® GDS portfolio of products from Neoprobe Corporation. The acquisition expands the company's dedicated breast care portfolio and product offerings as Devicor works towards its goal of building a \$500 million global medical device business.
- Construction began on a new Design and Education Center that grows the company's presence at its Sharonville, Ohio headquarters. The expansion is set to be completed in spring of 2012 and will help Mammotome continue its leadership in hands-on customer training.

"We've celebrated some great accomplishments over the past year, but we do so with our eyes firmly on the future," says Daulton. "Our number one priority in every step we take along the way is to work toward our mission of developing superior, minimally-invasive tools and technologies that help clinicians best diagnose and care for their patients."

About Mammotome

Mammotome, headquartered in Sharonville, Ohio, has more than 400 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Sold in more than 50 countries around the world, the Mammotome® product portfolio includes the Mammotome® Breast Biopsy System and tissue markers (MammoMARK®, MicroMARK®, and CorMARK®) used in breast disease diagnostic sampling and management. Since its introduction in 1995, more than 3.8 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Biopsy System. For more information, please visit www.mammotome.com.

About Devicor® Medical Products, Inc.



Reach over 10,000,000 people with one click

[LEARN MORE ▶](#)

Pictures of the Day



Photo courtesy: Bill Branson, U.S. National Cancer Institute

consumer.healthday.com

Second Cancer Often Same Type as the First, Study Finds



france24.com

Cancer drug 'scalpers' corner U.S. market



[US Oncology Research Affiliated Investigators Participated in Studies that will be Presented at the 2011 American Society of Hematology Annual Meeting and Exposition](#) [29 Nov 2011] PR Newswire

[Philips MicroDose Next Generation Mammography Solution Gains Traction with First North American Customers, Enabling Excellent Image Quality at a Low Radiation Dose](#) [29 Nov 2011] PR Newswire

[BSGI/MBI Shows Greater Sensitivity and Comparable Specificity When Compared to Ultrasound and Mammography](#) [29 Nov 2011] PR Newswire

[BSGI/MBI: Effective for Detecting Breast Cancer In Dense and Non-Dense Breasts](#) [29 Nov 2011] PR Newswire

[New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System](#) [29 Nov 2011] PR Newswire

[Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTIC-AACR San Antonio Breast Cancer Symposium](#) [29 Nov 2011] PR Newswire

[News from the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America \(RSNA\) in Chicago](#) [29 Nov 2011] PR Newswire

[New Study Supports Mammography Screening at 40](#) [29 Nov 2011] PR Newswire

[Dune Medical's MarginProbe Obtains Procedure Code for Reimbursement in Germany](#) [28 Nov 2011] PR Newswire